Curis Inc revenue
Curis Inc's revenue was $9.4m in fiscal 2025, down 13.4% on the year before. Since fiscal 2009 ($8.6m) it has grown at a compound 0.6% a year. Over the last twelve months it was $4.3m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 16 | 15 | 17 | 15 | 10 | 8 | 8 | 10 | 10 | 10 | 11 | 11 | 10 | 10 | 11 | 9 | 4 |
| Growth on the year before | — | +86.3% | −7.7% | +15.0% | −11.6% | −34.4% | −20.0% | −4.5% | +31.5% | +5.4% | −4.1% | +8.3% | −1.7% | −4.6% | −1.4% | +8.8% | −13.4% | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Curis Inc | $4.3m | -62.2% | -25.0% |
| Camp4 Therapeutics Corp | $4.2m | 40.2% | — |
| Ensysce Biosciences, Inc. | $4.5m | -39.3% | 14.6% |
| Ocugen, Inc. | $4.6m | -3.7% | 26.3% |
| Entrada Therapeutics, Inc. | $4.7m | -94.1% | — |
| Bolt Biotherapeutics, Inc. | $4.7m | 12.8% | -11.5% |
Compare with peers
- Camp4 Therapeutics Corp revenue
- Ensysce Biosciences, Inc. revenue
- Ocugen, Inc. revenue
- Entrada Therapeutics, Inc. revenue
- Bolt Biotherapeutics, Inc. revenue
Head to head: CAMP vs CRISCRIS vs ENSCCRIS vs OCGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies